Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

2710 Reed Road, Suite 160, Houston, United States

SuperGreenToday Dec. 25 at 1:32 AM

$PSTV

0 · Reply

moneytra1n Dec. 24 at 6:09 PM

$PSTV what an idiot. Sorry to say it but the boot fits.

1 · Reply

Scop102 Dec. 24 at 5:14 PM

$PSTV hold for new years riches . I know no more than u but its got that feel that everything about to drop into place :)

1 · Reply

Love_To_Learn Dec. 24 at 5:03 PM

$PSTV MAKE SURE THAT 0.5949 IS HOT*

1 · Reply

bambus3001 Dec. 24 at 5:01 PM

$PSTV Profis kaufen auch Weihnachten und werden im neuen Jahr extra feiern nachholen

0 · Reply

Love_To_Learn Dec. 24 at 5:00 PM

$AGRZ SORRY FOR MANIPULATION GAVE U FAT SCALP NOW 0.87 RENDERING FOR $PSTV MARC WHEN HE WAS ANNOYING

0 · Reply

Love_To_Learn Dec. 24 at 4:59 PM

$NCL REFILLING SOME TEMP HOLES BELOVED @chuckld MESSAGES ! $PSTV

0 · Reply

Love_To_Learn Dec. 24 at 4:55 PM

$PSTV 0.58 * RES CHECK

0 · Reply

Love_To_Learn Dec. 24 at 4:31 PM

$PSTV BROUGHT AGRZ DOWN

0 · Reply

Redd_bull Dec. 24 at 3:50 PM

$PSTV looking forward 2026. Hoping fof positive catalysts and phase 2 updates. Exciting times ahead. Wishing you all a Merry Christmas. Enjoy the festive break. 👍

0 · Reply

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 15 days ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 20 days ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 23 days ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 4 weeks ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 4 weeks ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 5 weeks ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 6 weeks ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 4:15 PM EDT - 7 weeks ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 4 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 4 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Jul 31, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 15, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 10, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 26, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025, 4:15 PM EDT - 6 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 24, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

May 30, 2025, 4:15 PM EDT - 7 months ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 23, 2025, 4:15 PM EDT - 7 months ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 14, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

May 8, 2025, 7:00 AM EDT - 8 months ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Apr 23, 2025, 8:00 AM EDT - 8 months ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Apr 15, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Mar 27, 2025, 7:42 PM EDT - 9 months ago

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 19, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Mar 11, 2025, 11:00 AM EDT - 10 months ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 10, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Mar 7, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 6, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Mar 5, 2025, 4:01 PM EST - 10 months ago

Plus Therapeutics Announces New Employment Inducement Grants

Mar 4, 2025, 2:06 PM EST - 10 months ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Feb 26, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Feb 24, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Feb 20, 2025, 7:30 AM EST - 10 months ago

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Feb 18, 2025, 7:30 AM EST - 11 months ago

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Dec 17, 2024, 7:30 AM EST - 1 year ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

SuperGreenToday Dec. 25 at 1:32 AM

$PSTV

0 · Reply

moneytra1n Dec. 24 at 6:09 PM

$PSTV what an idiot. Sorry to say it but the boot fits.

1 · Reply

Scop102 Dec. 24 at 5:14 PM

$PSTV hold for new years riches . I know no more than u but its got that feel that everything about to drop into place :)

1 · Reply

Love_To_Learn Dec. 24 at 5:03 PM

$PSTV MAKE SURE THAT 0.5949 IS HOT*

1 · Reply

bambus3001 Dec. 24 at 5:01 PM

$PSTV Profis kaufen auch Weihnachten und werden im neuen Jahr extra feiern nachholen

0 · Reply

Love_To_Learn Dec. 24 at 5:00 PM

$AGRZ SORRY FOR MANIPULATION GAVE U FAT SCALP NOW 0.87 RENDERING FOR $PSTV MARC WHEN HE WAS ANNOYING

0 · Reply

Love_To_Learn Dec. 24 at 4:59 PM

$NCL REFILLING SOME TEMP HOLES BELOVED @chuckld MESSAGES ! $PSTV

0 · Reply

Love_To_Learn Dec. 24 at 4:55 PM

$PSTV 0.58 * RES CHECK

0 · Reply

Love_To_Learn Dec. 24 at 4:31 PM

$PSTV BROUGHT AGRZ DOWN

0 · Reply

Redd_bull Dec. 24 at 3:50 PM

$PSTV looking forward 2026. Hoping fof positive catalysts and phase 2 updates. Exciting times ahead. Wishing you all a Merry Christmas. Enjoy the festive break. 👍

0 · Reply

Redd_bull Dec. 24 at 3:48 PM

$PSTV Always

0 · Reply

TechieGal Dec. 24 at 3:38 PM

$PSTV When you see someone posting every few minutes like this short seller then you know they can’t drop the price so they need to scare people so they can sell. I am holding and bought a little more today. Thanks for the discount

3 · Reply

Winning81 Dec. 24 at 3:22 PM

$PSTV this puppy is going to drop like a rock very soon! Get out while you still can. Don’t say I didn’t warn you😀

1 · Reply

Keywest20 Dec. 24 at 3:16 PM

$PSTV same to you!!! And happy new year 🎊 i just 🎆 ordered 5 pounds of stone crab claws for New Year’s Eve my wife will be so surprised 😳 good luck my friend

1 · Reply

Keywest20 Dec. 24 at 3:12 PM

$PSTV they will return shares as we get closer to Monday and they will set their stops guaranteed

1 · Reply

dang1976 Dec. 24 at 3:09 PM

$PSTV, Merry Christmas everyone! I’m holding!

0 · Reply

BioHunter1 Dec. 24 at 2:49 PM

$PSTV just horrible. Basically all shorts

0 · Reply

Love_To_Learn Dec. 24 at 2:27 PM

$PSTV GOOD GIRL BROUGHT VCIG DOWN

0 · Reply

Keywest20 Dec. 24 at 1:58 PM

$PSTV Shorts are paying 15.25% on borrowed shares!!!

0 · Reply

Love_To_Learn Dec. 24 at 1:29 PM

$PSTV TURING ON OUR DEATH TOUCH

0 · Reply

Love_To_Learn Dec. 24 at 1:22 PM

$PSTV U R BEING VERY CHEEKY TODAY MARC I LIKE IT OK LETS GO WITH THIS RANDOMNESS U HAVE GOING U IN A BIT OF A GOOFY MOOD TODAY I LIKE IT

0 · Reply

Love_To_Learn Dec. 24 at 1:19 PM

$PSTV NO HANG ON MWG KIDS OBSESSED WITH U

1 · Reply

Market Cap	81.74M
Revenue (ttm)	5.82M
Net Income (ttm)	-12.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	1.26
Profit Margin	-223.02%
Debt to Equity Ratio	0.00

Volume	1,527,900
Avg Vol	6,513,752
Day's Range	N/A - N/A
Shares Out	137.43M
Stochastic %K	28%
Beta	0.82
Analysts	Strong Sell
Price Target	$7.25